{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T15:17:50Z","timestamp":1779376670895,"version":"3.53.1"},"reference-count":137,"publisher":"Georg Thieme Verlag KG","issue":"05","license":[{"start":{"date-parts":[[2024,8,21]],"date-time":"2024-08-21T00:00:00Z","timestamp":1724198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:p>Patients with glioblastoma are among the cancer patients with the highest risk of developing venous thromboembolism (VTE). Long-term thromboprophylaxis is not generally prescribed because of the increased susceptibility of glioblastoma patients to intracranial hemorrhage. This review provides an overview of the current clinical standard for glioblastoma patients, as well as the molecular and genetic background which underlies the high incidence of VTE. The two main procoagulant proteins involved in glioblastoma-related VTE, podoplanin and tissue factor, are described, in addition to the genetic aberrations that can be linked to a hypercoagulable state in glioblastoma. Furthermore, possible novel biomarkers and future treatment strategies are discussed, along with the potential of sequencing approaches toward personalized risk prediction for VTE. A glioblastoma-specific VTE risk stratification model may help identifying those patients in which the increased risk of bleeding due to extended anticoagulation is outweighed by the decreased risk of VTE.<\/jats:p>","DOI":"10.1055\/s-0044-1789592","type":"journal-article","created":{"date-parts":[[2024,8,21]],"date-time":"2024-08-21T23:03:15Z","timestamp":1724281395000},"page":"421-434","source":"Crossref","is-referenced-by-count":9,"title":["Venous Thromboembolism in Patients with Glioblastoma: Molecular Mechanisms and Clinical Implications"],"prefix":"10.1055","volume":"125","author":[{"given":"Henri H.","family":"Versteeg","sequence":"first","affiliation":[{"name":"Division of Thrombosis and Hemostasis, Department of Medicine, Einthoven Laboratory for Vascular and Regenerative Medicine, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5816-9739","authenticated-orcid":false,"given":"Jeroen T.","family":"Buijs","sequence":"first","affiliation":[{"name":"Division of Thrombosis and Hemostasis, Department of Medicine, Einthoven Laboratory for Vascular and Regenerative Medicine, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0631-1307","authenticated-orcid":false,"given":"Maaike Y.","family":"Kapteijn","sequence":"additional","affiliation":[{"name":"Division of Thrombosis and Hemostasis, Department of Medicine, Einthoven Laboratory for Vascular and Regenerative Medicine, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Bakker","sequence":"additional","affiliation":[{"name":"Division of Thrombosis and Hemostasis, Department of Medicine, Einthoven Laboratory for Vascular and Regenerative Medicine, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan A. F.","family":"Koekkoek","sequence":"additional","affiliation":[{"name":"Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2024,8,21]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/neuonc\/noaa200","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013-2017","volume":"22","author":"Q T Ostrom","year":"2020","journal-title":"Neuro-oncol"},{"issue":"10","key":"ref2","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.3390\/cancers14102412","article-title":"Epidemiology of glioblastoma multiforme-literature review","volume":"14","author":"S Grochans","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"01","key":"ref3","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s11060-011-0738-7","article-title":"Improved survival time trends for glioblastoma using the SEER 17 population-based registries","volume":"107","author":"M Koshy","year":"2012","journal-title":"J Neurooncol"},{"issue":"04","key":"ref4","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ejca.2014.12.014","article-title":"Glioblastoma in England: 2007-2011","volume":"51","author":"A Brodbelt","year":"2015","journal-title":"Eur J Cancer"},{"issue":"03","key":"ref5","doi-asserted-by":"crossref","first-page":"e043208","DOI":"10.1136\/bmjopen-2020-043208","article-title":"Treatment approach and survival from glioblastoma: results from a population-based retrospective cohort study from Western Norway","volume":"11","author":"L S Bjorland","year":"2021","journal-title":"BMJ Open"},{"issue":"06","key":"ref6","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1097\/00005072-200606000-00001","article-title":"\u2018Pseudopalisading\u2019 necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis","volume":"65","author":"Y Rong","year":"2006","journal-title":"J Neuropathol Exp Neurol"},{"issue":"02","key":"ref7","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1750-3639.2007.00108.x","article-title":"Intravascular thrombosis in central nervous system malignancies: a potential role in astrocytoma progression to glioblastoma","volume":"18","author":"M Tehrani","year":"2008","journal-title":"Brain Pathol"},{"issue":"01","key":"ref8","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11060-015-1805-2","article-title":"Venous thromboembolism (VTE) and glioblastoma","volume":"124","author":"S Yust-Katz","year":"2015","journal-title":"J Neurooncol"},{"issue":"07","key":"ref9","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1111\/jth.15739","article-title":"Incidence and determinants of thrombotic and bleeding complications in patients with glioblastoma","volume":"20","author":"F HJ Kaptein","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"07","key":"ref10","doi-asserted-by":"crossref","first-page":"e1001275","DOI":"10.1371\/journal.pmed.1001275","article-title":"Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis","volume":"9","author":"F Horsted","year":"2012","journal-title":"PLoS Med"},{"issue":"04","key":"ref11","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1055\/s-0039-1688493","article-title":"Venous thromboembolism in brain tumors: risk factors, molecular mechanisms, and clinical challenges","volume":"45","author":"J Riedl","year":"2019","journal-title":"Semin Thromb Hemost"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1252417","DOI":"10.3389\/fmed.2023.1252417","article-title":"Oncogenes and cancer associated thrombosis: what can we learn from single cell genomics about risks and mechanisms?","volume":"10","author":"N Tawil","year":"2023","journal-title":"Front Med (Lausanne)"},{"issue":"27","key":"ref13","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1038\/s41388-023-02738-y","article-title":"Glioblastoma heterogeneity at single cell resolution","volume":"42","author":"D Eisenbarth","year":"2023","journal-title":"Oncogene"},{"issue":"06","key":"ref14","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1111\/jth.12242","article-title":"Coagulation-related gene expression profile in glioblastoma is defined by molecular disease subtype","volume":"11","author":"N Magnus","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"10","key":"ref15","doi-asserted-by":"crossref","first-page":"5281","DOI":"10.1002\/cam4.1757","article-title":"Trends and patterns of incidence of diffuse glioma in adults in the United States, 1973-2014","volume":"7","author":"K Li","year":"2018","journal-title":"Cancer Med"},{"key":"ref16","first-page":"197","volume-title":"Current standards of care in glioblastoma therapy","author":"C Fernandes","year":"2017"},{"issue":"02","key":"ref17","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3171\/jns.2001.95.2.0190","article-title":"A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival","volume":"95","author":"M Lacroix","year":"2001","journal-title":"J Neurosurg"},{"issue":"09","key":"ref18","first-page":"121","article-title":"Current trends in the surgical management and treatment of adult glioblastoma","volume":"3","author":"R M Young","year":"2015","journal-title":"Ann Transl Med"},{"issue":"10","key":"ref19","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"R Stupp","year":"2005","journal-title":"N Engl J Med"},{"issue":"11","key":"ref20","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1056\/NEJMoa1611977","article-title":"Short-course radiation plus temozolomide in elderly patients with glioblastoma","volume":"376","author":"J R Perry","year":"2017","journal-title":"N Engl J Med"},{"issue":"05","key":"ref21","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.trecan.2020.02.010","article-title":"MGMT status as a clinical biomarker in glioblastoma","volume":"6","author":"M Butler","year":"2020","journal-title":"Trends Cancer"},{"issue":"01","key":"ref22","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/nrneurol.2009.197","article-title":"MGMT promoter methylation in malignant gliomas: ready for personalized medicine?","volume":"6","author":"M Weller","year":"2010","journal-title":"Nat Rev Neurol"},{"issue":"06","key":"ref23","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.3171\/2012.9.JNS12504","article-title":"Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article","volume":"117","author":"O Bloch","year":"2012","journal-title":"J Neurosurg"},{"issue":"03","key":"ref24","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/neuonc\/noac216","article-title":"Palliative care and end-of-life care in adults with malignant brain tumors","volume":"25","author":"J AF Koekkoek","year":"2023","journal-title":"Neuro-oncol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3389\/fnmol.2019.00065","article-title":"Dexamethasone in glioblastoma multiforme therapy: mechanisms and controversies","volume":"12","author":"M Cenciarini","year":"2019","journal-title":"Front Mol Neurosci"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"727707","DOI":"10.3389\/fphar.2021.727707","article-title":"The prognostic effect of dexamethasone on patients with glioblastoma: a systematic review and meta-analysis","volume":"12","author":"L Zhou","year":"2021","journal-title":"Front Pharmacol"},{"issue":"06","key":"ref27","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1097\/CCO.0000000000000876","article-title":"Management of epilepsy in brain tumor patients","volume":"34","author":"P B van der Meer","year":"2022","journal-title":"Curr Opin Oncol"},{"issue":"S 04","key":"ref28","first-page":"iv73","article-title":"Thromboembolic disease in patients with high-grade glioma","volume":"14","author":"J R Perry","year":"2012","journal-title":"Neuro-oncol"},{"issue":"02","key":"ref29","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1538-7836.2009.03690.x","article-title":"Venous thromboembolism in malignant gliomas","volume":"8","author":"E O Jenkins","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"02","key":"ref30","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1215\/15228517-2006-035","article-title":"Venous thromboembolism and survival in patients with high-grade glioma","volume":"9","author":"R Simanek","year":"2007","journal-title":"Neuro-oncol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"e13027","DOI":"10.1200\/jco.2015.33.15_suppl.e13027","article-title":"Venous thromboembolism in patients with glioblastoma: Risk factors and prognostic importance","volume":"33","author":"N C Edwin","year":"2015","journal-title":"J Clin Oncol"},{"issue":"03","key":"ref32","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/1097-0142(20000801)89:3<640::AID-CNCR20>3.0.CO;2-E","article-title":"The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review","volume":"89","author":"L C Marras","year":"2000","journal-title":"Cancer"},{"issue":"04","key":"ref33","doi-asserted-by":"crossref","first-page":"601","DOI":"10.3171\/jns.2007.106.4.601","article-title":"Epidemiology of venous thromboembolism in 9489 patients with malignant glioma","volume":"106","author":"T J Semrad","year":"2007","journal-title":"J Neurosurg"},{"issue":"08","key":"ref34","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1111\/ene.15404","article-title":"Venous thromboembolic events in glioblastoma patients: an epidemiological study","volume":"29","author":"A Eisele","year":"2022","journal-title":"Eur J Neurol"},{"issue":"05","key":"ref35","first-page":"e2678","article-title":"Risk of venous thromboembolism in glioblastoma patients","volume":"10","author":"G Lim","year":"2018","journal-title":"Cureus"},{"issue":"08","key":"ref36","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1055\/s-0036-1592334","article-title":"Venous thromboembolism in patients with high-grade glioma","volume":"42","author":"D J Cote","year":"2016","journal-title":"Semin Thromb Hemost"},{"issue":"14","key":"ref37","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1182\/blood.2020007338","article-title":"Venous thromboembolism in cancer patients: a population-based cohort study","volume":"137","author":"F I Mulder","year":"2021","journal-title":"Blood"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/s12957-015-0592-8","article-title":"Venous thromboembolism in cancer patients: an underestimated major health problem","volume":"13","author":"J Khalil","year":"2015","journal-title":"World J Surg Oncol"},{"issue":"08","key":"ref39","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.3390\/cancers15082347","article-title":"Temozolomide and lomustine induce tissue factor expression and procoagulant activity in glioblastoma cells in vitro","volume":"15","author":"M Y Kapteijn","year":"2023","journal-title":"Cancers (Basel)"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"14698","DOI":"10.1038\/srep14698","article-title":"Risk of adverse vascular events in newly diagnosed glioblastoma multiforme patients treated with bevacizumab: a systematic review and meta-analysis","volume":"5","author":"X Li","year":"2015","journal-title":"Sci Rep"},{"issue":"05","key":"ref41","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/00063198-200109000-00013","article-title":"Thromboembolism in brain tumors","volume":"7","author":"D C Walsh","year":"2001","journal-title":"Curr Opin Pulm Med"},{"issue":"10","key":"ref42","first-page":"4309","article-title":"Retrospective study of venous thromboembolic and intracerebral hemorrhagic events in glioblastoma patients","volume":"29","author":"E Pan","year":"2009","journal-title":"Anticancer Res"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"617966","DOI":"10.3389\/fonc.2021.617966","article-title":"Seizures, edema, thrombosis, and hemorrhages: an update review on the medical management of gliomas","volume":"11","author":"M Zoccarato","year":"2021","journal-title":"Front Oncol"},{"issue":"16","key":"ref44","doi-asserted-by":"crossref","first-page":"4873","DOI":"10.1182\/bloodadvances.2022008086","article-title":"ICH in primary or metastatic brain cancer patients with or without anticoagulant treatment: a systematic review and meta-analysis","volume":"6","author":"M Giustozzi","year":"2022","journal-title":"Blood Adv"},{"issue":"04","key":"ref45","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1227\/00006123-198204000-00004","article-title":"Spontaneous intracranial hemorrhage caused by brain tumor: its incidence and clinical significance","volume":"10","author":"S Wakai","year":"1982","journal-title":"Neurosurgery"},{"issue":"05","key":"ref46","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1161\/01.RES.0000118600.91698.BB","article-title":"Comparative evaluation of FGF-2-, VEGF-A-, and VEGF-C-induced angiogenesis, lymphangiogenesis, vascular fenestrations, and permeability","volume":"94","author":"R Cao","year":"2004","journal-title":"Circ Res"},{"issue":"22","key":"ref47","doi-asserted-by":"crossref","first-page":"12081","DOI":"10.1073\/pnas.94.22.12081","article-title":"Intracerebral tumor-associated hemorrhage caused by overexpression of the vascular endothelial growth factor isoforms VEGF121 and VEGF165 but not VEGF189","volume":"94","author":"S Y Cheng","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"07","key":"ref48","doi-asserted-by":"crossref","first-page":"e334","DOI":"10.1016\/S1470-2045(22)00160-7","article-title":"2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19","volume":"23","author":"D Farge","year":"2022","journal-title":"Lancet Oncol"},{"issue":"10","key":"ref49","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1111\/jth.14564","article-title":"The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: Guidance from the SSC of the ISTH","volume":"17","author":"T F Wang","year":"2019","journal-title":"J Thromb Haemost"},{"issue":"10","key":"ref50","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"A A Khorana","year":"2008","journal-title":"Blood"},{"issue":"24","key":"ref51","doi-asserted-by":"crossref","first-page":"5377","DOI":"10.1182\/blood-2010-02-270116","article-title":"Prediction of venous thromboembolism in cancer patients","volume":"116","author":"C Ay","year":"2010","journal-title":"Blood"},{"issue":"08","key":"ref52","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1111\/jth.14824","article-title":"The Khorana score for prediction of venous thromboembolism in cancer patients: an individual patient data meta-analysis","volume":"18","author":"N van Es","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"06","key":"ref53","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1097\/CCO.0000000000000226","article-title":"Venous thrombosis in patients with high-grade glioma","volume":"27","author":"S Taillibert","year":"2015","journal-title":"Curr Opin Oncol"},{"issue":"02","key":"ref54","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/EJA.0000000000000710","article-title":"European guidelines on perioperative venous thromboembolism prophylaxis: neurosurgery","volume":"35","author":"D Faraoni","year":"2018","journal-title":"Eur J Anaesthesiol"},{"issue":"02","key":"ref55","first-page":"87","article-title":"Intracranial hemorrhage in setting of glioblastoma with venous thromboembolism","volume":"3","author":"M N Khoury","year":"2016","journal-title":"Neurooncol Pract"},{"issue":"25","key":"ref56","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1182\/blood-2017-02-767285","article-title":"Predicting the higher rate of intracranial hemorrhage in glioma patients receiving therapeutic enoxaparin","volume":"129","author":"C Mantia","year":"2017","journal-title":"Blood"},{"issue":"03","key":"ref57","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/neuonc\/noab198","article-title":"Management of venous thromboembolism in high-grade glioma: does low molecular weight heparin increase intracranial bleeding risk?","volume":"24","author":"J Jo","year":"2022","journal-title":"Neuro-oncol"},{"issue":"12","key":"ref58","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1093\/neuonc\/noac125","article-title":"Risk of intracranial hemorrhage with direct oral anticoagulants vs low molecular weight heparin in glioblastoma: a retrospective cohort study","volume":"24","author":"L Reed-Guy","year":"2022","journal-title":"Neuro-oncol"},{"issue":"01","key":"ref59","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/jth.14336","article-title":"Intracranial hemorrhage with direct oral anticoagulants in patients with brain tumors","volume":"17","author":"B J Carney","year":"2019","journal-title":"J Thromb Haemost"},{"issue":"05","key":"ref60","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/onco.13698","article-title":"Safety of direct oral anticoagulants in central nervous system malignancies","volume":"26","author":"A W Swartz","year":"2021","journal-title":"Oncologist"},{"issue":"09","key":"ref61","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1111\/j.1538-7836.2010.03973.x","article-title":"PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma","volume":"8","author":"J R Perry","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"08","key":"ref62","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMoa1814630","article-title":"Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer","volume":"380","author":"A A Khorana","year":"2019","journal-title":"N Engl J Med"},{"issue":"08","key":"ref63","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to prevent venous thromboembolism in patients with cancer","volume":"380","author":"M Carrier","year":"2019","journal-title":"N Engl J Med"},{"issue":"02","key":"ref64","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/jth.13590","article-title":"Physiologic and pathophysiologic roles of interaction between C-type lectin-like receptor 2 and podoplanin: partners from in utero to adulthood","volume":"15","author":"K Suzuki-Inoue","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref65","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.cell.2010.01.045","article-title":"Lymphangiogenesis: molecular mechanisms and future promise","volume":"140","author":"T Tammela","year":"2010","journal-title":"Cell"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3389\/fimmu.2012.00283","article-title":"Podoplanin: emerging functions in development, the immune system, and cancer","volume":"3","author":"J L Astarita","year":"2012","journal-title":"Front Immunol"},{"issue":"03","key":"ref67","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/jth.13604","article-title":"C-type lectin-like receptor 2 promotes hematogenous tumor metastasis and prothrombotic state in tumor-bearing mice","volume":"15","author":"T Shirai","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"06","key":"ref68","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1182\/bloodadvances.2020002998","article-title":"Glioblastoma cell populations with distinct oncogenic programs release podoplanin as procoagulant extracellular vesicles","volume":"5","author":"N Tawil","year":"2021","journal-title":"Blood Adv"},{"issue":"13","key":"ref69","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1182\/blood-2016-06-720714","article-title":"Podoplanin expression in primary brain tumors induces platelet aggregation and increases risk of venous thromboembolism","volume":"129","author":"J Riedl","year":"2017","journal-title":"Blood"},{"issue":"S 01","key":"ref70","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/j.thromres.2018.01.020","article-title":"The role of podoplanin in cancer-associated thrombosis","volume":"164","author":"P Mir Seyed Nazari","year":"2018","journal-title":"Thromb Res"},{"issue":"04","key":"ref71","doi-asserted-by":"crossref","first-page":"100758","DOI":"10.1016\/j.tranon.2020.100758","article-title":"Wild-type IDH1 and mutant IDH1 opposingly regulate podoplanin expression in glioma","volume":"13","author":"C Sun","year":"2020","journal-title":"Transl Oncol"},{"issue":"08","key":"ref72","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO Classification of Tumors of the Central Nervous System: a summary","volume":"23","author":"D N Louis","year":"2021","journal-title":"Neuro-oncol"},{"issue":"11","key":"ref73","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1182\/blood.2022017858","article-title":"Determining venous thromboembolism risk in patients with adult-type diffuse glioma","volume":"141","author":"K B Burdett","year":"2023","journal-title":"Blood"},{"issue":"01","key":"ref74","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1152\/physrev.00016.2011","article-title":"New fundamentals in hemostasis","volume":"93","author":"H H Versteeg","year":"2013","journal-title":"Physiol Rev"},{"issue":"08","key":"ref75","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1182\/blood-2003-10-3417","article-title":"Tissue factor-factor VIIa-specific up-regulation of IL-8 expression in MDA-MB-231 cells is mediated by PAR-2 and results in increased cell migration","volume":"103","author":"G M Hjortoe","year":"2004","journal-title":"Blood"},{"issue":"04","key":"ref76","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.bbrc.2006.04.005","article-title":"Protease-activated receptor-2 regulates vascular endothelial growth factor expression in MDA-MB-231 cells via MAPK pathways","volume":"344","author":"Y Liu","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"issue":"04","key":"ref77","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1055\/s-0039-1687895","article-title":"Role of tissue factor in tumor progression and cancer-associated thrombosis","volume":"45","author":"A MR Rondon","year":"2019","journal-title":"Semin Thromb Hemost"},{"issue":"S 01","key":"ref78","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1016\/S0049-3848(12)70020-8","article-title":"Tissue factor isoforms in cancer and coagulation: may the best isoform win","volume":"129","author":"B Kocat\u00fcrk","year":"2012","journal-title":"Thromb Res"},{"issue":"02","key":"ref79","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.thromres.2012.11.013","article-title":"Tumour and microparticle tissue factor expression and cancer thrombosis","volume":"131","author":"K Date","year":"2013","journal-title":"Thromb Res"},{"issue":"03","key":"ref80","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/j.1538-7836.2007.02369.x","article-title":"Microparticle-associated tissue factor activity: a link between cancer and thrombosis?","volume":"5","author":"M E Tesselaar","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"09","key":"ref81","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1002\/(SICI)1097-0142(19960501)77:9<1877::AID-CNCR18>3.0.CO;2-X","article-title":"Expression of tissue factor correlates with grade of malignancy in human glioma","volume":"77","author":"K Hamada","year":"1996","journal-title":"Cancer"},{"issue":"04","key":"ref82","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0009-9120(02)00312-0","article-title":"Tissue factor expression and angiogenesis in human glioma","volume":"35","author":"M Guan","year":"2002","journal-title":"Clin Biochem"},{"issue":"04","key":"ref83","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1158\/0008-5472.CAN-04-3376","article-title":"PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma","volume":"65","author":"Y Rong","year":"2005","journal-title":"Cancer Res"},{"issue":"02","key":"ref84","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.thromres.2012.09.020","article-title":"Intratumoral tissue factor expression and risk of venous thromboembolism in brain tumor patients","volume":"131","author":"J Thaler","year":"2013","journal-title":"Thromb Res"},{"issue":"01","key":"ref85","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ygyno.2017.04.021","article-title":"Evaluation of venous thrombosis and tissue factor in epithelial ovarian cancer","volume":"146","author":"J G Cohen","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"11","key":"ref86","doi-asserted-by":"crossref","first-page":"e0207387","DOI":"10.1371\/journal.pone.0207387","article-title":"Coagulation biomarkers and prediction of venous thromboembolism and survival in small cell lung cancer: a sub-study of RASTEN - a randomized trial with low molecular weight heparin","volume":"13","author":"E Gezelius","year":"2018","journal-title":"PLoS One"},{"issue":"11","key":"ref87","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1111\/j.1538-7836.2008.03156.x","article-title":"Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer","volume":"6","author":"A A Khorana","year":"2008","journal-title":"J Thromb Haemost"},{"issue":"22","key":"ref88","doi-asserted-by":"crossref","first-page":"6830","DOI":"10.1158\/1078-0432.CCR-09-0371","article-title":"Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy","volume":"15","author":"J I Zwicker","year":"2009","journal-title":"Clin Cancer Res"},{"key":"ref89","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.thromres.2018.04.009","article-title":"Extracellular vesicles exposing tissue factor for the prediction of venous thromboembolism in patients with cancer: a prospective cohort study","volume":"166","author":"N van Es","year":"2018","journal-title":"Thromb Res"},{"issue":"01","key":"ref90","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1182\/blood.V64.1.177.177","article-title":"Tissue factor in microvesicles shed from U87MG human glioblastoma cells induces coagulation, platelet aggregation, and thrombogenesis","volume":"64","author":"E Bastida","year":"1984","journal-title":"Blood"},{"issue":"02","key":"ref91","first-page":"378","article-title":"Circulating microparticles of glial origin and tissue factor bearing in high-grade glioma: a potential prothrombotic role","volume":"110","author":"M T Sartori","year":"2013","journal-title":"Thromb Haemost"},{"issue":"06","key":"ref92","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s00401-016-1620-7","article-title":"Mutant IDH1 and thrombosis in gliomas","volume":"132","author":"D Unruh","year":"2016","journal-title":"Acta Neuropathol"},{"issue":"07","key":"ref93","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1111\/j.1538-7836.2012.04754.x","article-title":"Microparticle-associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients","volume":"10","author":"J Thaler","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref94","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.2741\/e477","article-title":"Tissue factor: mechanisms of decryption","volume":"4","author":"L V Rao","year":"2012","journal-title":"Front Biosci (Elite Ed)"},{"issue":"02","key":"ref95","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1055\/s-0037-1613800","article-title":"The influence exerted by a restricted phospholipid microenvironment on the expression of tissue factor activity at the cell plasma membrane surface","volume":"83","author":"C Kunzelmann-Marche","year":"2000","journal-title":"Thromb Haemost"},{"issue":"38","key":"ref96","doi-asserted-by":"crossref","first-page":"13932","DOI":"10.1073\/pnas.0606411103","article-title":"Disulfide isomerization switches tissue factor from coagulation to cell signaling","volume":"103","author":"J Ahamed","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"07","key":"ref97","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1161\/ATVBAHA.117.309315","article-title":"Tissue factor prothrombotic activity is regulated by integrin-arf6 trafficking","volume":"37","author":"A S Rothmeier","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"S 01","key":"ref98","doi-asserted-by":"crossref","first-page":"S130","DOI":"10.1016\/j.thromres.2018.01.005","article-title":"The intersection of protein disulfide isomerase and cancer associated thrombosis","volume":"164","author":"J D Stopa","year":"2018","journal-title":"Thromb Res"},{"issue":"12","key":"ref99","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1038\/s41416-022-01968-3","article-title":"Tissue factor in cancer-associated thromboembolism: possible mechanisms and clinical applications","volume":"127","author":"S Koizume","year":"2022","journal-title":"Br J Cancer"},{"issue":"01","key":"ref100","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ccr.2009.12.020","article-title":"Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1","volume":"17","author":"R G Verhaak","year":"2010","journal-title":"Cancer Cell"},{"issue":"01","key":"ref101","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ccell.2017.06.003","article-title":"Tumor evolution of glioma-intrinsic gene expression subtypes associates with immunological changes in the microenvironment","volume":"32","author":"Q Wang","year":"2017","journal-title":"Cancer Cell"},{"issue":"03","key":"ref102","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ccr.2006.02.019","article-title":"Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis","volume":"9","author":"H S Phillips","year":"2006","journal-title":"Cancer Cell"},{"key":"ref103","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.thromres.2023.10.018","article-title":"RNA-sequencing to discover genes and signaling pathways associated with venous thromboembolism in glioblastoma patients: a case-control study","volume":"232","author":"M Y Kapteijn","year":"2023","journal-title":"Thromb Res"},{"issue":"11","key":"ref104","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1038\/s41416-020-0814-x","article-title":"IDH mutation in glioma: molecular mechanisms and potential therapeutic targets","volume":"122","author":"S Han","year":"2020","journal-title":"Br J Cancer"},{"issue":"17","key":"ref105","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1212\/WNL.0b013e3181f96282","article-title":"IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas","volume":"75","author":"C Houillier","year":"2010","journal-title":"Neurology"},{"issue":"05","key":"ref106","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3390\/cancers9050052","article-title":"Epidermal growth factor receptor cell proliferation signaling pathways","volume":"9","author":"P Wee","year":"2017","journal-title":"Cancers (Basel)"},{"issue":"07","key":"ref107","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1016\/j.ajpath.2015.02.023","article-title":"Molecular and genomic alterations in glioblastoma multiforme","volume":"185","author":"I Crespo","year":"2015","journal-title":"Am J Pathol"},{"issue":"08","key":"ref108","first-page":"2164","article-title":"Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo","volume":"51","author":"A J Ekstrand","year":"1991","journal-title":"Cancer Res"},{"issue":"02","key":"ref109","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","article-title":"The somatic genomic landscape of glioblastoma","volume":"155","author":"C W Brennan","year":"2013","journal-title":"Cell"},{"issue":"16","key":"ref110","doi-asserted-by":"crossref","first-page":"7727","DOI":"10.1073\/pnas.91.16.7727","article-title":"A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity","volume":"91","author":"R Nishikawa","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"05","key":"ref111","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1182\/blood-2009-10-250639","article-title":"Oncogenic epidermal growth factor receptor up-regulates multiple elements of the tissue factor signaling pathway in human glioma cells","volume":"116","author":"N Magnus","year":"2010","journal-title":"Blood"},{"issue":"24","key":"ref112","doi-asserted-by":"crossref","first-page":"10068","DOI":"10.1158\/0008-5472.CAN-08-2067","article-title":"Tissue factor regulation by epidermal growth factor receptor and epithelial-to-mesenchymal transitions: effect on tumor initiation and angiogenesis","volume":"68","author":"C C Milsom","year":"2008","journal-title":"Cancer Res"},{"issue":"17","key":"ref113","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/sj.onc.1201756","article-title":"PTEN mutations in gliomas and glioneuronal tumors","volume":"16","author":"E M Duerr","year":"1998","journal-title":"Oncogene"},{"issue":"05","key":"ref114","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00401-003-0748-4","article-title":"PTEN methylation and expression in glioblastomas","volume":"106","author":"N Baeza","year":"2003","journal-title":"Acta Neuropathol"},{"issue":"06","key":"ref115","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1158\/0008-5472.CAN-08-1547","article-title":"Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD\/activator protein-1 transcriptional activity","volume":"69","author":"Y Rong","year":"2009","journal-title":"Cancer Res"},{"issue":"10","key":"ref116","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1373\/clinchem.2009.123695","article-title":"Increased tissue factor expression is associated with reduced survival in non-small cell lung cancer and with mutations of TP53 and PTEN","volume":"55","author":"S Regina","year":"2009","journal-title":"Clin Chem"},{"issue":"04","key":"ref117","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1093\/neuonc\/nos055","article-title":"Expression of podoplanin in human astrocytic brain tumors is controlled by the PI3K-AKT-AP-1 signaling pathway and promoter methylation","volume":"14","author":"H Peterziel","year":"2012","journal-title":"Neuro-oncol"},{"issue":"02","key":"ref118","doi-asserted-by":"crossref","first-page":"246","DOI":"10.3390\/biomedicines10020246","article-title":"Impact of CDKN2A\/B homozygous deletion on the prognosis and biology of IDH-mutant glioma","volume":"10","author":"L E Huang","year":"2022","journal-title":"Biomedicines"},{"issue":"7216","key":"ref119","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/nature07385","article-title":"Comprehensive genomic characterization defines human glioblastoma genes and core pathways","volume":"455","author":"Cancer Genome Atlas Research Network","year":"2008","journal-title":"Nature"},{"issue":"05","key":"ref120","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1158\/0008-5472.CAN-13-1951","article-title":"P14ARF suppresses tumor-induced thrombosis by regulating the tissue factor pathway","volume":"74","author":"A Zerrouqi","year":"2014","journal-title":"Cancer Res"},{"issue":"05","key":"ref121","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00384-011-1164-1","article-title":"Mutations of p53 and K-ras correlate TF expression in human colorectal carcinomas: TF downregulation as a marker of poor prognosis","volume":"26","author":"B Rao","year":"2011","journal-title":"Int J Colorectal Dis"},{"issue":"15","key":"ref122","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1182\/blood.2020007488","article-title":"Genomic profiling identifies somatic mutations predicting thromboembolic risk in patients with solid tumors","volume":"137","author":"A Dunbar","year":"2021","journal-title":"Blood"},{"key":"ref123","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.thromres.2022.11.013","article-title":"Targeted DNA sequencing to identify genetic aberrations in glioblastoma that underlie venous thromboembolism; a cohort study","volume":"221","author":"M Y Kapteijn","year":"2023","journal-title":"Thromb Res"},{"issue":"52","key":"ref124","doi-asserted-by":"crossref","first-page":"49289","DOI":"10.1074\/jbc.M108069200","article-title":"Vascular endothelial growth factor induction of the angiogenic phenotype requires Ras activation","volume":"276","author":"K N Meadows","year":"2001","journal-title":"J Biol Chem"},{"issue":"12","key":"ref125","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1093\/neuonc\/nou106","article-title":"Biomarkers predictive of venous thromboembolism in patients with newly diagnosed high-grade gliomas","volume":"16","author":"J Thaler","year":"2014","journal-title":"Neuro-oncol"},{"key":"ref126","doi-asserted-by":"crossref","first-page":"e621","DOI":"10.1016\/j.wneu.2018.09.177","article-title":"Significance and prognostic value of the coagulation profile in patients with glioblastoma: implications for personalized therapy","volume":"121","author":"S E Navone","year":"2019","journal-title":"World Neurosurg"},{"issue":"02","key":"ref127","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s11060-015-1840-z","article-title":"A prospective multicenter study of venous thromboembolism in patients with newly-diagnosed high-grade glioma: hazard rate and risk factors","volume":"124","author":"M B Streiff","year":"2015","journal-title":"J Neurooncol"},{"issue":"01","key":"ref128","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1538-7836.2009.03680.x","article-title":"High platelet count associated with venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS)","volume":"8","author":"R Simanek","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref129","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s00428-005-0133-x","article-title":"Podoplanin is expressed in subsets of tumors of the central nervous system","volume":"448","author":"J Shibahara","year":"2006","journal-title":"Virchows Arch"},{"issue":"04","key":"ref130","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/j.bbrc.2006.08.171","article-title":"Inhibition of tumor cell-induced platelet aggregation using a novel anti-podoplanin antibody reacting with its platelet-aggregation-stimulating domain","volume":"349","author":"Y Kato","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"issue":"03","key":"ref131","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1158\/2326-6066.CIR-15-0060","article-title":"CAR T cells targeting podoplanin reduce orthotopic glioblastomas in mouse brains","volume":"4","author":"S Shiina","year":"2016","journal-title":"Cancer Immunol Res"},{"issue":"08","key":"ref132","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1093\/neuonc\/noad059","article-title":"Epidemiology, biology, and management of venous thromboembolism in gliomas: an interdisciplinary review","volume":"25","author":"J Jo","year":"2023","journal-title":"Neuro-oncol"},{"issue":"04","key":"ref133","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/bjh.12163","article-title":"Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec study)","volume":"160","author":"J I Zwicker","year":"2013","journal-title":"Br J Haematol"},{"issue":"06","key":"ref134","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1002\/ijc.20965","article-title":"Recombinant adeno-associated virus (rAAV) expressing TFPI-2 inhibits invasion, angiogenesis and tumor growth in a human glioblastoma cell line","volume":"115","author":"N Yanamandra","year":"2005","journal-title":"Int J Cancer"},{"issue":"05","key":"ref135","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/neup.12018","article-title":"Anti-tissue factor (TF9-10H10) treatment reduces tumor cell invasiveness in a novel migratory glioma model","volume":"33","author":"P N Harter","year":"2013","journal-title":"Neuropathology"},{"issue":"11","key":"ref136","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1111\/j.1538-7836.2009.03553.x","article-title":"Ixolaris, a tissue factor inhibitor, blocks primary tumor growth and angiogenesis in a glioblastoma model","volume":"7","author":"T C Carneiro-Lobo","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref137","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s40364-023-00504-6","article-title":"Tissue factor (coagulation factor III): a potential double-edge molecule to be targeted and re-targeted toward cancer","volume":"11","author":"S E Ahmadi","year":"2023","journal-title":"Biomark Res"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0044-1789592.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T22:31:03Z","timestamp":1745965863000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0044-1789592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,21]]},"references-count":137,"journal-issue":{"issue":"05","published-online":{"date-parts":[[2025,4,29]]},"published-print":{"date-parts":[[2025,5]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0044-1789592","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,21]]}}}